Literature DB >> 2817765

[Pituitary adenoma treated with a somatostatin analog].

C Houdent1, M F Armangau, J M Kuhn, T Delangre, M Tadie, E Clavier, J P Basuyau, G Sassolas, L M Wolf.   

Abstract

We studied for over 7 months the use of SMS 201-995, in 1 woman with pituitary adenoma. Eight years after surgical and irradiation therapy, adenoma relapsed with hyperthyroidism (T4 L = 71pmol/l, TSH = 5.3 mU/l, subunit: 309 micrograms/l) and was complicated by meningitis. It was invasive and removed only partly. SMS therapy, 100 micrograms SC q 8 h, allowed partial reduction of clinical hyperthyroidism and decreased TSH and alpha subunit of 47%. Increased dosage and changing route of administration did not increase efficacy. A modest decrease of adenoma was probably caused by several reasons. In summary in an adenoma unusual by the extremely high value of alpha subunit in contrast with modest value of TSH, SMS therapy allowed partial control only.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817765

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  2 in total

1.  TSH-Secreting Pituitary Adenoma: Current Management and Review.

Authors:  M K Kole; J Goldman; J P Rock
Journal:  Skull Base Surg       Date:  1997

Review 2.  Medical management of thyrotropin-secreting pituitary adenomas.

Authors:  Paolo Beck-Peccoz; Luca Persani
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.